111 related articles for article (PubMed ID: 21728981)
21. Oncogenic amino acid substitutions in the inhibitory rap-1A protein cause it to adopt a ras-p21-like conformation as computed using molecular dynamics.
Chen JM; Brandt-Rauf PW; Pincus MR
J Biomol Struct Dyn; 1996 Jun; 13(6):925-33. PubMed ID: 8832375
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the guanine-nucleotide exchange protein, SOS, identified from molecular dynamics calculations. Selective inhibition of oncogenic ras-p21.
Chie L; Chen JM; Friedman FK; Chung DL; Amar S; Michl J; Yamaizumi Z; Brandt-Rauf PW; Pincus MR
J Protein Chem; 1999 Nov; 18(8):875-9. PubMed ID: 10839624
[TBL] [Abstract][Full Text] [Related]
23. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
Krzesaj P; Adler V; Feinman RD; Miller A; Silberstein M; Yazdi E; Pincus MR
Ann Clin Lab Sci; 2024 Mar; 54(2):137-148. PubMed ID: 38802154
[TBL] [Abstract][Full Text] [Related]
24. Molecular dynamics analysis of the structures of ras-guanine nucleotide exchange protein (SOS) bound to wild-type and oncogenic ras-p21. Identification of effector domains of SOS.
Chen JM; Friedman FK; Hyde MJ; Monaco R; Pincus MR
J Protein Chem; 1999 Nov; 18(8):867-74. PubMed ID: 10839623
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the predicted structures of loops in the ras-SOS protein bound to a single ras-p21 protein with the crystallographically determined structures in SOS bound to two ras-p21 proteins.
Smith S; Hyde M; Pincus MR
Protein J; 2005 Aug; 24(6):391-8. PubMed ID: 16323045
[TBL] [Abstract][Full Text] [Related]
26. A peptide from the GAP-binding domain of the ras-p21 protein as well as azatyrosine block ras-induced maturation of Xenopus oocytes.
Chung DL; Brandt-Rauf P; Murphy RB; Nishimura S; Yamaizumi Z; Weinstein IB; Pincus MR
Biochem Biophys Res Commun; 1991 Dec; 181(3):1378-84. PubMed ID: 1764089
[TBL] [Abstract][Full Text] [Related]
27. Site-specific phosphorylation of raf in cells containing oncogenic ras-p21 is likely mediated by jun-N-terminal kinase.
Adler V; Bowne W; Michl J; Sookraj KA; Ikram K; Pestka S; Izotova L; Zenilman M; Friedman FK; Qu Y; Pincus MR
Ann Clin Lab Sci; 2008; 38(1):47-56. PubMed ID: 18316782
[TBL] [Abstract][Full Text] [Related]
28. Differences in patterns of activation of MAP kinases induced by oncogenic ras-p21 and insulin in oocytes.
Ranginwale M; Smith S; Flom J; Chie L; Kanovsky M; Chung D; Friedman FK; Robinson RC; Brandt-Rauf PW; Yamaizumi Z; Michl J; Pincus MR
Exp Cell Res; 2001 Sep; 269(1):162-9. PubMed ID: 11525649
[TBL] [Abstract][Full Text] [Related]
29. Comparison of molecular dynamics averaged structures for complexes of normal and oncogenic ras-p21 with SOS nucleotide exchange protein, containing computed conformations for three crystallographically undefined domains, suggests a potential role of these domains in ras signaling.
Duncan T; Chen JM; Friedman FK; Hyde M; Chie L; Pincus MR
Protein J; 2004 Apr; 23(3):217-28. PubMed ID: 15200053
[TBL] [Abstract][Full Text] [Related]
30. Anti-Cancer Tumor Cell Necrosis of Epithelial Ovarian Cancer Cell Lines Depends on High Expression of HDM-2 Protein in Their Membranes.
Thadi A; Gleeson EM; Khalili M; Shaikh MF; Goldstein E; Morano WF; Daniels LM; Grandhi N; Glatthorn H; Richard SD; Campbell PM; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2020 Sep; 50(5):611-624. PubMed ID: 33067207
[TBL] [Abstract][Full Text] [Related]
31. Loop domain peptides from the SOS ras-guanine nucleotide exchange protein, identified from molecular dynamics calculations, strongly inhibit ras signaling.
Chie L; Friedman FK; Duncan T; Chen JM; Chung D; Pincus M
Protein J; 2004 Apr; 23(3):229-34. PubMed ID: 15200054
[TBL] [Abstract][Full Text] [Related]
32. An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21.
Chie L; Adler V; Friedman FK; Chung D; Pincus MR
Protein J; 2004 Apr; 23(3):235-8. PubMed ID: 15200055
[TBL] [Abstract][Full Text] [Related]
33. Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function.
Kuo ML; Chou YW; Chau YP; Huang TS
Mol Carcinog; 1997 Apr; 18(4):221-31. PubMed ID: 9142217
[TBL] [Abstract][Full Text] [Related]
34. Evidence that oocyte maturation induced by an oncogenic ras-p21 protein and insulin is mediated by overlapping yet distinct mechanisms.
Chung DL; Joran A; Friedman F; Robinson R; Brandt-Rauf PW; Weinstein IB; Ronai Z; Baskin L; Dykes DC; Murphy RB
Exp Cell Res; 1992 Dec; 203(2):329-35. PubMed ID: 1459198
[TBL] [Abstract][Full Text] [Related]
35. A protein methyl transferase, PRMT5, selectively blocks oncogenic ras-p21 mitogenic signal transduction.
Chie L; Cook JR; Chung D; Hoffmann R; Yang Z; Kim Y; Pestka S; Pincus MR
Ann Clin Lab Sci; 2003; 33(2):200-7. PubMed ID: 12817625
[TBL] [Abstract][Full Text] [Related]
36. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells.
Kanovsky M; Raffo A; Drew L; Rosal R; Do T; Friedman FK; Rubinstein P; Visser J; Robinson R; Brandt-Rauf PW; Michl J; Fine RL; Pincus MR
Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12438-43. PubMed ID: 11606716
[TBL] [Abstract][Full Text] [Related]
37. Treatment of ras-induced cancers by the F-actin-bundling drug MKT-077.
Tikoo A; Shakri R; Connolly L; Hirokawa Y; Shishido T; Bowers B; Ye LH; Kohama K; Simpson RJ; Maruta H
Cancer J; 2000; 6(3):162-8. PubMed ID: 10882332
[TBL] [Abstract][Full Text] [Related]
38. Molecular dynamics of the H-ras gene-encoded p21 protein; identification of flexible regions and possible effector domains.
Dykes DC; Friedman FK; Dykes SL; Murphy RB; Brandt-Rauf PW; Pincus MR
J Biomol Struct Dyn; 1993 Dec; 11(3):443-58. PubMed ID: 8129867
[TBL] [Abstract][Full Text] [Related]
39. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
